Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Status:
Recruiting
Trial end date:
2023-01-25
Target enrollment:
Participant gender:
Summary
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide
physicians with a new clinical option to control platinum resistant ovarian cancer (PROC)
progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an
acceptable safety profile in patients with PROC in a published Phase I/II study. Therefore,
the combination of afuresertib plus weekly paclitaxel could represent a clinically meaningful
step forward in the clinical management of these difficult-to-treat patients with PROC.